Long‐term efficacy and safety of dutasteride 0.5 mg in Korean men with androgenetic alopecia: 5‐year data demonstrating clinical improvement with sustained efficacy
The Journal of Dermatology · 2024
DOI: 10.1111/1346-8138.17138 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Dermatology, 2024. Verfasst von Sangmin Choi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Kyung Hee University Hospital at Gangdong, Kyung Hee University School of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Alopecia, Dutasteride, 5-alpha Reductase Inhibitors. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 19 Literaturangaben. Gefördert von: National Research Foundation of Korea.
Abstract (Originalsprache)
Dutasteride 0.5 mg is a dual inhibitor of 5α‐reductase type I and II and was approved in Korea in 2009 for treating androgenetic alopecia (AGA) in men. We investigated the 5‐year efficacy and safety of dutasteride 0.5 mg in Korean men with AGA using the basic and specific (BASP) classification. This retrospective analysis included 99 male AGA patients aged ≥18 years who were treated with dutasteride 0.5 mg for at least 5 years from October 2009 to December 2016 at Kyung Hee University Hospital in Gangdong. Patient photographs were scored using the BASP classification, and the Investigator Global Assessment (IGA) was performed using a seven‐point scale. Patient improvement (IGA score ≥1) and prevention of disease progression (IGA score ≥0) were 89.9% (89/99) and 93.9% (93/99), respectively. According to the BASP classification, 52.5% (52/99) of the basic type, 75% (15/20) of the specific F type, and 82.2% (60/73) of the specific V type showed clinical improvement after 5 years of treatment. Dutasteride demonstrated long‐term safety and efficacy in Korean male patients with AGA over a period of at least 5 years, with results comparable to those of other long‐term efficacy studies of finasteride 1 mg in male patients with AGA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Kyung Hee University Hospital at Gangdong, Kyung Hee University School of Medicine, Seoul, Korea.
ORCID-Profile: Sangmin Choi, Soon-Hyo Kwon, Woo-Young Sim, Bark-Lynn Lew
Förderung
- National Research Foundation of Korea
Zitieren
APA
Choi, S., Kwon, S. H., Sim, W. Y., & Lew, B. L. (2024). Long‐term efficacy and safety of dutasteride 0.5 mg in Korean men with androgenetic alopecia: 5‐year data demonstrating clinical improvement with sustained efficacy. The Journal of Dermatology. https://doi.org/10.1111/1346-8138.17138
Vancouver
Choi S, Kwon SH, Sim WY, Lew BL. Long‐term efficacy and safety of dutasteride 0.5 mg in Korean men with androgenetic alopecia: 5‐year data demonstrating clinical improvement with sustained efficacy. The Journal of Dermatology. 2024. doi:10.1111/1346-8138.17138
BibTeX
@article{Choi2024,
author = {Choi, Sangmin and Kwon, Soon-Hyo and Sim, Woo-Young and Lew, Bark-Lynn},
title = {Long‐term efficacy and safety of dutasteride 0.5 mg in Korean men with androgenetic alopecia: 5‐year data demonstrating clinical improvement with sustained efficacy},
journal = {The Journal of Dermatology},
year = {2024},
doi = {10.1111/1346-8138.17138}
}
EUVIMED